Equillium (EQ)
(Delayed Data from NSDQ)
$1.67 USD
+0.11 (7.05%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EQ 1.67 +0.11(7.05%)
Will EQ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EQ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EQ
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
EQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
Other News for EQ
Short interest on energy stocks up in March; APA and EQT most shorted, COP least shorted
EQ Inc. Celebrates a Profitable, Growth-Fueled Quarter
EQ Inc. Reports Profitable Fourth Quarter and 2023 Year End Financial Results
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)